EMA Gives Oncopeptides’ Multiple Myeloma Drug The Thumbs Up; Keeps US FDA In Loop
Company’s Request For EU Conditional Approval Flipped To Full Marketing Authorization
FDA Was A Silent Observer At Most EMA Meetings For Evaluating Melphalan Flufenamide • Source: Shutterstock 
